Recombinant Human IFN-alpha I/IFN17 Protein (RP01899)

Recombinant Human IFN-alpha I/IFN17 Protein was determined by SDS-PAGE with Coomassie Blue, showing a band at 20-25 kDa.

Recombinant Human IFN-alpha I/IFN17 Protein cytotoxicity assay using TF-1 cells. The ED₅₀ for this effect is 0.17‑0.68 ng/mL, corresponding to a specific activity of 1.47×10⁶~5.88×10⁶ units/mg.

All(2)|

货号: RP01899

详细信息

种属

Human

表达宿主

HEK293 cells

Calculated MW

20.14 kDa

Observed MW

20-25 kDa

标签

C-His

纯度

> 97% by SDS-PAGE.

内毒素

<0.01EU/μg of the protein by LAL method.

制剂

Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4.

描述

Recombinant Human IFN-alpha I/IFN17 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Cys24-Asp189) of Human IFN-alpha I/IFN17 (Accession #NP_067091.1) fused with a His tag at the C-terminus.

储存

Store at -20℃.Store the lyophilized protein at -20℃ to -80 ℃ up to 1 year from the date of receipt.
After reconstitution, the protein solution is stable at -20℃ for 3 months, at 2-8℃ for up to 1 week.未开盖的干粉蛋白在 -20°C至-80°C可保存12个月；
复溶之后，蛋白溶液在-20°C及以下可保存3个月，在2-8℃可保存1周。

生物活性

Measured in a cell cytotoxicity assay using TF-1 cells. The ED₅₀ for this effect is 0.17‑0.68 ng/mL, corresponding to a specific activity of 1.47×10⁶~5.88×10⁶ units/mg.

复溶

Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stablizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.收到重组蛋白产品之后请检查蛋白冻干粉末是否贴于瓶底，如果粉末浮起，开盖之前请先低温离心。将蛋白用说明书中指定的缓冲液复溶至0.1-0.5 mg/mL（请注意蛋白复溶浓度不能低于0.1 mg/mL），室温平衡5-10 min保证充分溶解，复溶过程中请不要剧烈涡旋及吹打蛋白溶液。如需长期储存，建议复溶时添加载体蛋白或者稳定剂（如0.1% BSA, 5% HSA, 10% FBS 或者 5% 海藻糖），同时将复溶后的蛋白溶液按照需求进行分装，储存于-20°C至-80°C，随取随用，避免反复冻融。

蛋白复溶计算器

请在蛋白复溶计算器中输入蛋白总质量和所需终浓度，快速计算您需要添加溶液的体积吧！

客户数据及评论 (0)

折叠内容

背景信息

Interferons (IFN) are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors . Human IFNA2 was originally cloned in the early ‘80s and now more than a dozen closely related IFN alpha subtypes have been identified in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology . Structurally, type I IFNs belong to the class of five helicalbundle cytokines, with the IFNA subtypes containing 2 conserved disulfide bonds . There is not a mouse homolog for IFNA17, but mature human IFNA17 shares 58% aa sequence identity with chimpanzee IFNA17. The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha -subunit) and IFNAR2 (beta -subunit) . Individual IFNA subtypes are known to display unique efficacies to viral protection . IFNA17 has been shown to be potent against HIV-1 activity . Human IFNA17 is the only IFNA subtype identified with antiviral activity but a reduced ability to activate NK cells . A mutation in IFNA17, Ile184Arg, is associated with an increased risk for cervical cancer.

基因ID

3451

Swiss Prot

P01571

别名

Interferon alpha-17; IFN-alpha-17; Interferon alpha-88; Interferon alpha-I'; LeIF I; Interferon alpha-T，IFNA17

研究领域